Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the ...

Shares of Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) fell 13% on Wednesday following the announcement that its Phase 3 COMPASS ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

The COMPASS PWS trial was a 12-week, randomized, double-blind, placebo-controlled, parallel-group study that included 175 patients aged 5 to 30 years with PWS.

In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Tiziana Life Sciences ...

A new study led by Mass General Brigham investigators compared the effects of repeated intravenous (IV) ketamine and ...

The Food and Drug Administration (FDA) has approved Enbumyst ™, a nasal spray formulation of bumetanide, for the treatment of edema associated with congestive heart failure (CHF), and hepatic and ...

Acadia Pharmaceuticals was testing the drug, an intranasal formulation of the oxytocin analogue carbetocin, for its potential ...

Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales in 2025 and highlights a strong pipeline outlook.

This spray formulation of bumetanide demonstrated a 33% faster absorption rate than oral bumetanide, according to clinical ...

“Most people don’t like to watch,” the pharmacist told me as I stared at the thin needle piercing my arm. After more than a year of lockdowns and disrupted economies and millions of lost lives, this ...